ストックスクリーナーアプリを入手
13.36
1.44%
0.19
Myriad Genetics Inc (MYGN) 最新ニュース
Barclays PLC Raises Stake in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Stock Might Gain From the New Recognition of RiskScore Study - Yahoo Finance
PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR
Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR
Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire
Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan
Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR
Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year LowTime to Sell? - MarketBeat
Myriad Genetics stock hits 52-week low at $13.86 amid challenges - Investing.com Canada
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? - Yahoo Finance
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Myriad Genetics stock hits 52-week low at $13.86 amid challenges By Investing.com - Investing.com South Africa
Clinical Oncology Next Generation Sequencing Market Top - openPR
How To Trade (MYGN) - Stock Traders Daily
State Street Corp Buys 359,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $13.00 at Bank of America - MarketBeat
Why Myriad Genetics, Inc. Shares Soared - AOL
Analysts Offer Predictions for Myriad Genetics Q1 Earnings - MarketBeat
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing - The Manila Times
Myriad Genetics Provides Update on Discussions with - GlobeNewswire
Myriad Genetics Fights to Preserve GeneSight Coverage as UnitedHealthcare Plans 2025 Restrictions - StockTitan
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member - The Manila Times
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock To Gain? - Barchart
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - The Manila Times
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - GlobeNewswire
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partnrs - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Coverage Initiated by Analysts at UBS Group - MarketBeat
Disciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Cancer Biopsy Market Trends, Key Drivers, and Regional Outlook - openPR
PARP Inhibitor Biomarkers Market Key Players AnalysisMyriad - openPR
Pharmacogenomics Global Market Report: Key Insights and Market - openPR
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium - The Manila Times
Myriad Genetics Unveils Breakthrough Breast Cancer Detection Tools at SABCS 2024 - StockTitan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partners - MarketBeat
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment - The Manila Times
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad - GlobeNewswire
Myriad Genetics' Prolaris Test Retains Elite NCCN Status for 10th Year in Prostate Cancer Diagnosis - StockTitan
Wellington Management Group LLP Sells 1,545,842 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Shareholders in Myriad Genetics (NASDAQ:MYGN) have lost 41%, as stock drops 7.0% this past week - Simply Wall St
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts - Investing.com Canada
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts By Investing.com - Investing.com South Africa
Point72 Asset Management L.P. Grows Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Verition Fund Management LLC Has $2.44 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Charles Schwab Investment Management Inc. Acquires 41,374 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
How to Take Advantage of moves in (MYGN) - Stock Traders Daily
Edgestream Partners L.P. Makes New Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Fisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $27.36 Average PT from Analysts - MarketBeat
0.72%
大文字化:
|
ボリューム (24 時間):